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Background: The venous extracranial abnormalities in multiple sclerosis (MS) provide
a new perspective in the treatment. The primary endpoint of our study was to evaluate the
occurrence of venous obstructions in the extracranial venous pathway and the secondary
endpoint to assess the effect of angioplasty on the clinical disability.
Methods: In MS patients with 2 or more of the required 5 sonographic criteria, under
local anaesthesia selective catheter venography (CV) of the azygous (AZY) and the
internal jugular veins (IJVs) was performed.
Results: In our study 158 consecutive MS patients - 39 relapsing-remitting and 119 with
progressive course of disease were included. In 6/158 patients (3.8%) CV did not reveal
any vascular abnormality. The left IJV was more often affected (86%). Restenosis occurred
in 21%. No major side effect was observed. In our study no stents were used. The brain
biopsy tissue of the patients with the tumefactive form of MS demonstrated inflammatory
perivenular changes with intact arteriolar wall. Also an intima thickening of IJV was
found. The important improvement of clinical disability in the relapsing-remitting group
was achieved (p0.001). MS patients with the progressive course of disease reported an
amelioration of the fatigue headache, spasms, bladder dysfunction and quality of life.
Conclusion: Our results support the contribution of venous obstructions in the
extracranial venous pathway to the clinical picture of MS. The removal of venous
abnormalities may importantly influence the degree of clinical disability. Recently, a close
association between venous extracranial abnormalities and the presence of heart disease
was reported.
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Introduction: Bariatric surgery proposed for treatment of obesity is often related with
different types of complications and side effects.
Ghrelin, a recently discovered neuropeptide which is predominantly produced in the
gastric fundus, is the only known hormone stimulating food intake (orexigenic hormone).
Catheter-directed left Gastric Artery Chemical Embolization (GACE) performed in
animal models showed to decrease blood ghrelin levels and lead to weight loss.
Here we provide our preliminary results of the First-In-Man study of Left Gastric
Artery Embolization (GAE) safety and efficacy in obese patients.
Methods: 5 patients with different degrees of obesity underwent left GAE with BeadBlock
Embolic Bead 300–500m microspheres (Biocompatibles UK Limited, Chapman House,
Farnham Business Park, Weydon Lane Farnham, Surrey, GU9 8QL, UK).
Gastroscopy was performed in all patients before and after GAE and at 1 week follow
up to rule out significant initial gastritis or ulcer and any worsening after the procedure.
Blood Ghrelin level was also measured before the procedure as well as at 1, 2, 3 and 4
weeks follow up.
Observation on Ghrelin levels and patients’ weight is planned at 3, 6 and 12 month
follow up.
Results: There was no case of periprocedural complications. 3 of 5 patients complained
about slight pain in epigastrium after embolization during first few hours after the
embolization, but control gogastroscopy did not reveal any impairments.
All patients reported significantly decreased appetite in first days after procedure.
Weight loss was observed in all patients at 1 month follow up: mean initial weight -
128.1224.4kg was decreased to 114.8621.3kg and mean initial Body Mass Index
(BMI) - 42.266.8 was decreased to 37.865.7.
Conclusions: Early follow-up has demonstrated that GAE is safe and feasible. It may
become a less invasive and effective method for treatment of obesity.
Further controlled studies enrolling larger number of patients is underway performed to
confirm these initial findings.
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Acute and subacute ischemia of the legs in acute and subacute femoropopliteal bypass
occlusion is a dramatic situation that endangers the survival of the limbs, depending on the
severity of the ischemia. Different therapy options like percutaneous mechanical throm-
bectomy procedures, which include rotation thrombectomy, have become available in
recent years in addition to local lysis and surgical thrombectomy. Rotational thrombec-
tomy with the Straub Rotarex® system as an endovascular therapy option has demon-
strated promising results leading to amputation-free survical in multiple studies. We
recently provided data in 22 Patients with acute femoropopliteal bypass occlusion were we
examined the feasibility of the Rotarex® system in this indication. A technical success rate
of 82 % was demonstrated. During a follow up period of 6 months no reinterventions in
these patients had to be performed. We now provide patency rates in 21 patients of our
study group after a follow up period of 12 months. The average ABI after 12 months was
0,80 0,1. One patients showed a hemodynamic restenosis in a Nitinolstent distal to the
femoropopliteal bypass which was implanted in the index procedure. No reocclusion of
the femoropopliteal bypasses occurred in all patients.
6 months
follow up
12 months
follow up
Followed up patients 21/22 21/22
Rutherford stage I (15 patients) I (14 patients)
II (6 patients) II (7 patients)
Walking capacity 323 meter 312 meter
Ankle brachial index (ABI) 0,81 0.1 0,80 0.1
Death 0/21 0/21
Reinterventions 0/21 1/21
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